Filing Details
- Accession Number:
- 0001645470-19-000044
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-08-09 17:14:01
- Reporting Period:
- 2019-07-25
- Accepted Time:
- 2019-08-09 17:14:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1528172 | Endonovo Therapeutics Inc. | ENDV | Pharmaceutical Preparations (2834) | 452552528 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1645470 | Brian Alan Collier | 6320 Canoga Avenue 15Th Floor Woodland Hills CA 91367 | Ceo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2019-07-25 | 15,000 | $0.01 | 24,873,797 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-07-25 | 10,000 | $0.01 | 24,883,797 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-07-26 | 12,000 | $0.01 | 24,895,797 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-07-31 | 2,000 | $0.01 | 24,897,797 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-08-07 | 15,000 | $0.01 | 24,912,797 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-08-07 | 2,000 | $0.01 | 24,914,797 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-08-07 | 2,000 | $0.01 | 24,916,797 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-08-07 | 2,000 | $0.01 | 24,918,797 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2019-08-07 | 2,000 | $0.01 | 24,920,797 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |